These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 23313356

  • 1. Homocysteine-lowering therapy with folic acid is effective in cardiovascular disease prevention in patients with kidney disease: a meta-analysis of randomized controlled trials.
    Qin X, Huo Y, Xie D, Hou F, Xu X, Wang X.
    Clin Nutr; 2013 Oct; 32(5):722-7. PubMed ID: 23313356
    [Abstract] [Full Text] [Related]

  • 2. Folic acid therapy and cardiovascular disease in ESRD or advanced chronic kidney disease: a meta-analysis.
    Qin X, Huo Y, Langman CB, Hou F, Chen Y, Matossian D, Xu X, Wang X.
    Clin J Am Soc Nephrol; 2011 Mar; 6(3):482-8. PubMed ID: 21088292
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of folic acid supplementation in cardiovascular disease prevention: an updated meta-analysis of randomized controlled trials.
    Yang HT, Lee M, Hong KS, Ovbiagele B, Saver JL.
    Eur J Intern Med; 2012 Dec; 23(8):745-54. PubMed ID: 22884409
    [Abstract] [Full Text] [Related]

  • 4. Meta-analysis of folic acid supplementation trials on risk of cardiovascular disease and risk interaction with baseline homocysteine levels.
    Miller ER, Juraschek S, Pastor-Barriuso R, Bazzano LA, Appel LJ, Guallar E.
    Am J Cardiol; 2010 Aug 15; 106(4):517-27. PubMed ID: 20691310
    [Abstract] [Full Text] [Related]

  • 5. Homocysteine-lowering therapy does not lead to reduction in cardiovascular outcomes in chronic kidney disease patients: a meta-analysis of randomised, controlled trials.
    Pan Y, Guo LL, Cai LL, Zhu XJ, Shu JL, Liu XL, Jin HM.
    Br J Nutr; 2012 Aug 15; 108(3):400-7. PubMed ID: 22244447
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of folic acid supplementation in stroke prevention: new insight from a meta-analysis.
    Huo Y, Qin X, Wang J, Sun N, Zeng Q, Xu X, Liu L, Xu X, Wang X.
    Int J Clin Pract; 2012 Jun 15; 66(6):544-51. PubMed ID: 22607506
    [Abstract] [Full Text] [Related]

  • 7. Folic Acid Supplementation and the Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials.
    Li Y, Huang T, Zheng Y, Muka T, Troup J, Hu FB.
    J Am Heart Assoc; 2016 Aug 15; 5(8):. PubMed ID: 27528407
    [Abstract] [Full Text] [Related]

  • 8. Effect of folic acid supplementation on the progression of carotid intima-media thickness: a meta-analysis of randomized controlled trials.
    Qin X, Xu M, Zhang Y, Li J, Xu X, Wang X, Xu X, Huo Y.
    Atherosclerosis; 2012 Jun 15; 222(2):307-13. PubMed ID: 22209480
    [Abstract] [Full Text] [Related]

  • 9. Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements.
    Clarke R, Armitage J.
    Semin Thromb Hemost; 2000 Jun 15; 26(3):341-8. PubMed ID: 11011852
    [Abstract] [Full Text] [Related]

  • 10. The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis.
    Jardine MJ, Kang A, Zoungas S, Navaneethan SD, Ninomiya T, Nigwekar SU, Gallagher MP, Cass A, Strippoli G, Perkovic V.
    BMJ; 2012 Jun 13; 344():e3533. PubMed ID: 22695899
    [Abstract] [Full Text] [Related]

  • 11. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis.
    Heinz J, Kropf S, Luley C, Dierkes J.
    Am J Kidney Dis; 2009 Sep 13; 54(3):478-89. PubMed ID: 19359080
    [Abstract] [Full Text] [Related]

  • 12. Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials.
    B-Vitamin Treatment Trialists' Collaboration.
    Am Heart J; 2006 Feb 13; 151(2):282-7. PubMed ID: 16442889
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease.
    Dierkes J, Domröse U, Ambrosch A, Bosselmann HP, Neumann KH, Luley C.
    Clin Nephrol; 1999 Feb 13; 51(2):108-15. PubMed ID: 10069646
    [Abstract] [Full Text] [Related]

  • 18. Controlled trials of very high dose folic acid, vitamins B12 and B6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD.
    Gonin JM, Nguyen H, Gonin R, Sarna A, Michels A, Masri-Imad F, Bommareddy G, Chassaing C, Wainer I, Loya A, Cary D, Barker LF, Assefi A, Greenspan R, Mahoney D, Wilcox CS.
    J Nephrol; 2003 Feb 13; 16(4):522-34. PubMed ID: 14696754
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial.
    Bostom AG, Carpenter MA, Kusek JW, Hunsicker LG, Pfeffer MA, Levey AS, Jacques PF, McKenney J, FAVORIT Investigators.
    Am Heart J; 2006 Sep 13; 152(3):448.e1-7. PubMed ID: 16923411
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.